Skip to content
EmergingResearch compound

PP‑405

Experimental scalp compound for hair loss; the data are mostly from the lab, and it is not proven in humans.

PP-405 vial

DETAILED OVERVIEW

What is PP-405?

PP-405 is an experimental compound for hair loss, applied to the scalp, developed by a company called Pelage Pharmaceuticals. It is not approved anywhere, it is not available as a routine treatment, and it is only being tried in humans in clinical trials. It is being studied for hormone-related hair thinning (androgenetic alopecia).

It blocks a protein that carries one of the products of sugar breakdown into the cell's energy-producing part (the mitochondrion). As a result the cell produces energy another way, which according to laboratory research may wake up the dormant stem cells in hair follicles and start a new growth phase. Its mode of action differs from finasteride and minoxidil. It is not proven to work in humans: it was well tolerated in the early trial, but no efficacy paper has appeared in a scientific journal yet, and long-term safety is unknown. Because there are no human data, it is to be avoided in pregnancy and while breastfeeding.

Developer

Pelage Pharmaceuticals; from University of California, Los Angeles research

Status

In clinical trials (phase 1/2a, 2024-2025); not approved

Mechanism of action

Blocks the pyruvate carrier; wakes stem cells, not hormone-blocking

Evidence

Strong preclinical mechanism; no PP-405-specific clinical efficacy published yet

Access

Clinical trial only; not available as a routine treatment

Data console

Lab data

Classification-
StructureN/A
Molecular weightN/A
Target area-
Storage2–8°C
Stability~30 days reconstituted

Safety

Side effects, stop signs, contraindications

Side effects · 3

  • Early clinical phase – limited human safety data: PP-405 is in phase 1/2a; phase 1 reported good tolerability, but the full side-effect profile is still accruing.
  • Local scalp reaction (expected): the topical form may cause local irritation (redness, itching); exact rates will come from ongoing trials.
  • Unknown long-term effect: as this is an entirely new metabolic target (mitochondrial pyruvate carrier), long-term human safety is not yet known; not available as a routine treatment.

Contraindications · 3

  • Investigational, not approved: human use outside a clinical trial cannot be supported – no approved indication or dose.
  • Pregnancy and breastfeeding: avoid due to lack of human data.
  • Broken, inflamed scalp; known hypersensitivity to the active or the vehicle.

Related Hair & Skin

Same therapeutic category

Studies

Related research and clinical findings

Telegram

Have a question about PP‑405?

Educational hair and skin info from official sources (PubMed, FDA, EMA). Does NOT replace medical consultation. Talk to a dermatologist!

Personalized consultation

Want a detailed conversation tailored to your data?

Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.

Fill out the form

~5–7 min · prep questionnaire · confidential · GDPR-compliant

MolekulaX Editorial Team·Source-verified · PubMed · FDA · EMA
Updated: October 14, 2026

The information here is strictly for educational and scientific purposes. It does not replace medical advice or clinical consultation, and it does not encourage illegal substance or pharmaceutical use. Data is sourced. When in doubt, consult your doctor.